Literature DB >> 7866404

Autosomal dominant spondylarthropathy due to a type II procollagen gene (COL2A1) point mutation.

A Winterpacht1, M Hilbert, U Schwarze, S Mundlos, J Spranger, B Zabel.   

Abstract

Osteoarthrosis represents a very common disease with heterogeneous etiology. In some pedigrees linkage of the condition with the type II collagen gene (COL2A1) has been established, but information on the underlying gene defect is still incomplete as only one mutation causing this phenotype has been identified. We analyzed the COL2A1 gene in a 27-year-old woman and her 47-year-old mother presenting with severe premature osteoarthrosis and X-ray signs compatible with mild spondyloepiphyseal dysplasia. Examination of the complete gene in both patients was done by amplification of all 54 exons, screening of the PCR products by SSCP-analysis, and subsequent sequencing. In mother and daughter a G to A transition at the 5'-end of exon 21 was detected, leading to a substitution of serine for glycine at position 274 of the triple helical domain. The mutation was not present in unaffected family members or in healthy control individuals. The autosomal dominant spondylarthropathies may represent the less severe entities of the clinical spectrum of type II collagenopathies.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7866404     DOI: 10.1002/humu.1380040405

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  2 in total

1.  Non-radioactive multiplex-SSCP analysis: detection of a new type II procollagen gene (COL2A1) mutation.

Authors:  A Winterpacht; K Hilbert; U Schwarze; B Zabel
Journal:  Hum Genet       Date:  1995-04       Impact factor: 4.132

2.  A novel retinoic acid-response element requires an enhancer element mediator for transcriptional activation.

Authors:  Laura R Harris; Olli-Pekka Kamarainen; Minna Sevakivi; Gwen C Miller; James W Clarke; Jennifer L Potter; Laura C Bridgewater
Journal:  Biochem J       Date:  2004-10-01       Impact factor: 3.857

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.